Inflammation and endothelial dysfunction in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 2, 2006, Pages 115-117

  Gonzalez Gay, Miguel A ^a   Gonzalez Juanatey, Carlos ^a   Martin, Javier ^b  

^a HOSPITAL XERAL CALDE   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Endothelial dysfunction; Flow mediated endothelial dependent vasodilation; IL 6; Rheumatoid arthritis; TNF

Indexed keywords

ACETYLCHOLINE; ADALIMUMAB; ARGININE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPITOPE; HLA DR ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; METHOTREXATE; METHYLPREDNISOLONE; NITRIC OXIDE; SELECTIN; TETRAHYDROBIOPTERIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INCIDENCE; LEUKOCYTE; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; MORTALITY; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOCYTE; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION;

EID: 33744790891     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (38)

1. GOODSON N, MARKS J, LUNT M, SYMMONS D: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
2. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular Morbidity and Mortality in Women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
3. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
4. SHOENFELD Y, GERLI R, DORIA A et al.: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005: 112: 3337-47.
5. DEL RINCÓN I, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
6. DEL RINCON I, WILLIAMS K, STERN MP, FREEMAN GL, O'LEARY DH, ESCALANTE A: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40.
7. SATTAR N, McCAREY DW, CAPELL H. McINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
8. GONZALEZ-JUANATEY C, LLORCA J, TESTA A, REVUELTA, J GARCIA-PORRUA C, GONZALEZ-GAY MA: Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82: 407-13.
9. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PINEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
10. GOODSON NJ, SYMMONS DP, SCOTT DG, BUNN D, LUNT M, SILMAN AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow-up study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
11. TURESSON C: Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des 2004; 10: 129-43.
12. GONZALEZ-GAY MA; GONZALEZ-JUANATEY C, LOPEZ-DIAZ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2006 (in press).
13. LIBBY P, RIDKER PM, MASERI A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
14. BIJL M: Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med 2003; 61: 273-7.
15. MONCADA S: Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci 1997; 811: 60-7.
16. IGNARRO LJ: Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999; 19: 51-71.
17. WALLBERG-JONSSON S, CVETKOVIC JT, SUNDQVIST KG, LEFVERT AK. RANTAPAADAHLQVIST S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29: 875-82.
18. VITA JA, KEANEY JF Jr: Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640-2.
19. NADAR S, BLANN AD, LIP GY: Endothelial dysfunction: methods of assessment and application to hypertension. Curr Pharm Des 2004; 10: 3591-605.
20. GOKCE N, KEANEY JF Jr, HUNTER LM et al.: Risk stratification for postoperative cardiovascular events via non-invasive assessment of endothelial function: a prospective study. Circulation. 2002; 105: 1567-72.
21. BERGHOLM R, LEIRISALO-REPO M, VEHKAVAARA S, MAKIMATTILA S, TASKINEN MR, YKI-JARVINEN H: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22: 1637-41.
22. HANSEL S, LASSIG G, PISTROSCH F, PASSAUER J: Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003; 170: 177-80.
23. CELERMAJER DS, SORENSEN KE, GOOCH VM et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
24. CORRETTI MC, ANDERSON TJ, BENJAMIN EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
25. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
26. VAUDO G, MARCHESI S, GERLI R et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63: 31-5.
27. BACON PA, RAZA K, BANKS MJ, TOWNEND J, KITAS GD: The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002; 21: 1-17.
28. HERMANN C, ASSMUS B, URBICH C, ZEIHER AM, DIMMELER S: Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 402-9.
29. YOSHIZUMI M, PERRELLA MA, BURNETT JC Jr, LEE ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-9.
30. NAKAMURA M, YOSHIDA H, ARAKAWA N, SAITOH S, SATOH M, HIRAMORI K: Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol 2000; 36: 487-92.
31. IMPERATO AK, BINGHAM CO 3RD, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22: S108-14.
32. HÜRLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
33. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006 (in press).
34. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A, GARCIA-PORRUA C, LLORCA J, GONZALEZ-GAY MA: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing longterm treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004:51: 447-50.
35. GONZALEZ-JUANATEY C, LLORCA J, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-3.
36. SATTAR N, MCINNES IB: Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.
37. DESSEIN PH, JOFFE BI, SINGH S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7: R634-43.
38. DESSEIN PH, JOFFE BI: Suppression of circulating interleukin-6 concentration is associated with decreased endothelial activation in rheumatoid arthritis.Clin Exp Rheumatol 2006; 24: 161-7.